Drugs / EMI-137
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03470259 | Jun 2018 → Dec 2019 | metastatic malignant neoplasm in the lymph nodes, thyroid gland papillary carcinoma | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 1 | NCT03205501 | Feb 2017 → Mar 2019 | Barrett esophagus, esophageal cancer | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03360461 | Feb 2018 → Feb 2020 | colon carcinoma, metastatic malignant neoplasm in the lymph nodes | University of Leeds | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EMI-137 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03360461 ↗ |
| Known as | GE-137 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297745 ↗ |
| Modality | Peptide | “labeling a small peptide to a fluorescent fluorophore” NCT03205501 ↗ |
| Route | Intravenous | “Intravenous administration of 0.13 mg/kg of the fluorescent tracer EMI-137 approximately 2.5 hours prior to the endoscopy procedure.” NCT03205501 ↗ |
| Target | MET | “fluorescent tracer specifically targeting c-Met” NCT03205501 ↗ |